Abstract
Promethazine hydrochloride, Phenergan, is a phenothiazine derivative with antihistaminic (H1), sedative, antiemetic, anticholinergic, and antimotion sickness properties. These properties have made promethazine a candidate for use in environments such as microgravity, which provoke emesis and motion sickness. Recently, we evaluated carotid baroreceptor-cardiac reflex responses during two Space Shuttle missions 18 to 20 hr after the 50 mg intramuscular administration of promethazine. Because the effects of promethazine on autonomic cardiovascular mechanisms in general and baroreflex function in particular were not known, we were unable to exclude a possible influence of promethazine on our results. Our purpose was to determine the ground-based effects of promethazine on autonomic cardiovascular control. Because of promethazine’s antihistaminic and anticholinergic properties, we expected that a 50-mg intramuscular injection of promethazine would affect sympathetically and vagally mediated cardiovascular mechanisms. Eight healthy young subjects, five men and three women, were studied at rest in recumbency. All reported drowsiness as a result of the promethazine injection; most also reported nervous excitation, dry mouth, and fatigue. Three subjects had significant reactions: two reported excessive anxiety and one reported dizziness. Measurements were performed immediately prior to injection and 3.1 ± 0.1 and 19.5 ± 0.4 hr postinjection. We found no significant effect of promethazine on resting mean R-R interval, arterial pressure, R-R interval power spectra, carotid baroreflex function, and venous plasma catecholamine levels.
Footnotes
-
Send reprint requests to: Dr. Troy E. Brown, KRUG Life Sciences, Inc., 1290 Hercules, Suite 120, PL/261, Houston, TX 77058.
-
↵1 This work was supported by grants from the Department of Veterans Affairs, the National Institutes of Health (HL22296) and the National Aeronautics and Space Administration (NAS9-16046 and NAG9-412).
-
↵2 Current address: KRUG Life Sciences, Inc., 1290 Hercules, Suite 120, Mail Code PL/261, Houston, TX 77058.
-
↵3 In this article, we use the terms “respiratory frequency” to signify R-R interval power between 0.20 and 0.30 Hz, “low frequency” to signify power between 0.05 and 0.15 Hz, and “very low frequency” to signify power below 0.05 Hz (0 Hz excluded). The 0.05 to 0.15 Hz range was chosen to encompass R-R interval frequencies that are considered to reflect baroreflex related vagal and sympathetic nerve traffic to the human heart (Koh et al., 1994). Resting humans also have R-R interval spectral power at lower frequencies (below 0.05 Hz) which may be related to thermoregulation (Kitney, 1987) and fluctuations in peripheral vascular resistance (Akselrod et al., 1985).
- Abbreviations:
- Baroreflex
- carotid baroreceptor-cardiac reflex response
- STS
- Space Transportation System
- Received July 22, 1996.
- Accepted April 9, 1997.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|